Related Experiment Video
Updated: May 27, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Human uric acid transporter 1 (hURAT1): an inhibitor structure-activity relationship (SAR) study
M F Wempe1, B Quade, P Jutabha
1School of Pharmacy, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045, USA. Michael.Wempe@ucdenver.edu
Nucleosides, Nucleotides & Nucleic Acids
|December 3, 2011
Summary
Researchers synthesized novel compounds and found that a negative charge is essential for potent inhibition of the human urate transporter 1 (hURAT1). This discovery aids in developing new treatments for conditions related to urate levels.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Biochemistry
Background:
- The human urate transporter 1 (hURAT1) plays a crucial role in regulating urate reabsorption in the kidneys.
- Dysregulation of hURAT1 is implicated in hyperuricemia and related conditions like gout.
- Developing selective hURAT1 inhibitors is a key therapeutic strategy.
Purpose of the Study:
- To synthesize and characterize novel (2-ethylbenzofuran-3-yl)(substituted-phenyl)methanone compounds.
- To investigate the in vitro inhibitory activity of these compounds against hURAT1.
- To elucidate the structure-activity relationships governing hURAT1 inhibition.
Main Methods:
- Chemical synthesis of a series of substituted methanone derivatives.
- In vitro functional assays using Xenopus oocytes expressing human hURAT1.
- Electrophysiological recordings to measure urate transport inhibition.
Main Results:
- The synthesized compounds demonstrated varying degrees of hURAT1 inhibition.
- A formal negative charge on the inhibitor molecule was identified as a critical requirement for potent binding to the positively charged hURAT1 pocket.
- Electronically donating or withdrawing groups on the phenyl ring significantly modulated inhibitory potency.
Conclusions:
- The presence of an anion is a fundamental requirement for hURAT1 substrates and inhibitors.
- Structure-activity relationship analysis provides insights into designing more effective hURAT1 inhibitors.
- These findings contribute to the development of novel therapeutic agents for managing urate homeostasis.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...